Take-home message {#FPar41}
=================

In this updated and extended systematic review and meta-analysis, we found a high incidence of sepsis across all regions; one out of four sepsis patients did not survive their hospital stay. Substantial gaps remain regarding data availability from low- and middle-income countries, the lack of community-based studies and inherent limitations of epidemiological research based on administrative data, highlighting the urgent need for improved epidemiological sepsis surveillance.

Introduction {#Sec1}
============

Sepsis is the dysregulated immune response to infection that leads to life-threatening organ dysfunction \[[@CR1]\]. It is a medical emergency associated with high mortality and long-term disability in survivors \[[@CR2]\]. In the USA (US), sepsis was identified as the most expensive condition in the hospital setting in 2011, responsible for 6.2% of the aggregate costs for all hospitalizations, or 23.7 billion USD, annually \[[@CR3]\]. In 2017, the World Health Organization (WHO) member states declared that the improvement of sepsis prevention, recognition, and treatment is a global health priority \[[@CR4]\]. In a systematic review and meta-analysis published in 2016, we estimated that more than 19 million annual severe sepsis cases occur worldwide, with at least five million deaths \[[@CR5]\]. A recent study from the Institute for Health Metrics and Evaluation (IHME) on the global burden of sepsis \[[@CR6]\] estimated 48.9 million incident sepsis cases and 11 million sepsis-related deaths worldwide in 2017. These estimates primarily used the Global Burden of Disease (GBD) 2017 Study cause of death estimates, with additional sepsis-specific death certificate data from four countries, and employed complex modelling to produce global estimates. Compared to previous estimates from cohort studies \[[@CR5]\], the incidence estimated by IHME is considerably higher. IHME data also suggest a decrease in sepsis incidence by approximately 37% between 1990 and 2017, contrary to the results from several individual studies that observed an increase in sepsis incidence over time \[[@CR5]\]. To better understand these conflicting data, we aimed to compile recent evidence on population-level sepsis incidence and mortality, particularly in LMICs, and to compare incidence estimates with respect to WHO region, observation years and sepsis case definition.

Methods {#Sec2}
=======

The review followed a predesigned protocol registered in PROSPERO (CRD42019136286).

Search strategy and eligibly criteria {#Sec3}
-------------------------------------

The literature search included (1) an updated search of the 2016 review \[[@CR5]\], (2) an extended search aiming to increase the number of studies from LMICs, and (3) hand search and expert queries for regions with limited data availability. We searched 13 databases for studies on population-level sepsis incidence with no language or publication restrictions: PubMed, EMBASE, LILACS, African Journals Online, OpenGREY, MedCarib, Index Medicus for the WHO Eastern Mediterranean Region, South East Asia Region, Western Pacific Region and African Region, IndMed, Web of Science, and WHOLIS. The full list of search terms is provided in the Supplement M1. In short, we (1) used the same search terms as in our previous review \[[@CR5]\] and updated it for the time frame between 05/2015 and 02/2019. We (2) added a search covering studies published between 01/1979 and 02/2019 that combined a list of sepsis terms with individual LMIC country names, according to the World Bank classification of countries, and specific search terms for LMICs as suggested by the EPOC group LMIC filters applied to the title and abstract of the studies (<https://epoc.cochrane.org/lmic-filters>).

We included studies that reported on population-level sepsis incidence or prevalence in adults, including studies that reported observed sepsis cases in hospitals, ICUs, Emergency Departments (ED), or a community. The term population-level refers to studies that report sepsis incidence rates for a defined population. Sepsis had to be defined according to sepsis-1/2 criteria for severe sepsis \[[@CR7], [@CR8]\], sepsis-3 criteria \[[@CR1]\], sepsis-relevant ICD-9/ICD-10 codes \[[@CR9]\], or implicit ICD-9/10-case identification (combined infection and organ dysfunction codes, known as Angus implementation \[[@CR10]\]). We accepted minor modification of the clinical criteria, e.g. in the limits of physiological parameters or if laboratory testing was unavailable. We excluded studies on sepsis incidence among hospital admission, studies on sepsis without organ dysfunction according to sepsis-1/2 criteria, and studies limited to sub-groups of sepsis, causative pathogens, selected patient groups, or treatment units (e.g. surgical ICUs). Studies with insufficient reporting on methodology were excluded.

Data compilation {#Sec4}
----------------

Abstracts were reviewed by two independent investigators (LM, CFS) and those considered to fulfil the inclusion criteria underwent full-text review by the same two investigators. Discrepancies were resolved by a third reviewer (KER). Non-English articles were assessed by native speakers with medical backgrounds. Extracted data included study location and methodology, number and age of patients, cases of sepsis observed, number of deaths from sepsis, sepsis in-hospital mortality rate, population denominator, and sepsis incidence, prevalence, and mortality per 100,000 population. Missing population data were requested from the authors or identified in national census databases. If there was a distinction between sepsis patients and observed sepsis episodes, the number of episodes was included for analysis. In this systematic review and meta-analysis update, sepsis is defined as an infection complicated by organ dysfunction, in accordance with sepsis-3, formerly known as severe sepsis. This includes cases of septic shock. We did not investigate the epidemiology of sepsis without organ failure. Studies that met the inclusion criteria were assessed for risk of bias using the tool suggested by Hoy et al. by two independent investigators \[[@CR11]\].

Statistical analyses {#Sec5}
--------------------

Two outcomes were considered for meta-analysis: (a) Population-level incidence rates, and (b) mortality rates of sepsis. Different calculations and standardizations used in the original studies may lead to a method-dependent overestimation of between-study variance. Therefore, our analyses are based on the reported numbers of observed hospital sepsis cases and population data. We included the most recent years or time frames reported in the studies in the meta-analysis. From studies that applied alternative definitions to the same data source, we prioritized sepsis-3 over sepsis-2, explicit over implicit ICD-based case definitions, and the most recent years of observation reported. Details of this selection process are described in the Supplement M2. We utilized meta-analytic random-effects models to perform the meta-analyses. A random intercept Poisson regression model was used for hospital- and ICU-treated sepsis incidence rates. For the meta-analyses of the mortality of hospital- and ICU-treated sepsis, we used a logistic random intercept model. Between-study heterogeneity was expressed by the standard deviation of the random intercepts (denoted by *τ*). Model parameters were back transformed to present the results as number of cases per 100,000 person-years (incidence rates) or the per cent of patients who died (mortality). For better interpretation, we additionally report the estimated averages across the studies obtained by numerical integration (for detailed explanations see Supplement M3).

The Poisson and the logistic random-effects models were extended to meta-regression models to investigate differences in incidence and mortality rates (a) across WHO regions (African Region (AFR), European region (EURO), Pan-American Region (PAR), Western Pacific Region (WPR)), and (b) arising from different sepsis case definitions {clinical criteria (sepsis-1 \[[@CR7]\], -2 \[[@CR8]\] or -3 \[[@CR1]\]) vs. ICD-case identification (implicit \[[@CR10]\] or explicit case identification \[[@CR9]\])}. The multi-parameter *F*-test \[[@CR12]\] as well as pairwise post hoc tests with *p* values adjusted for multiple testing \[[@CR13]\] were used for statistical inference in the meta-regression models. The specifications of all models are described in the Supplement. We present 95% Poisson-confidence intervals (CIs) for estimated incidence rates of the single studies and 95% Wilson score intervals for mortality rates. For the meta-analytic estimates of the overall incidence and mortality rate, we provide 95% CIs as well as 95% prediction intervals.

All statistical analyses were conducted within the R (Version 3.6.0; R core team, 2019) software environment. We used the metarate, metaprop, and metareg functions from the R package meta \[[@CR14]\] and the glht function from the multcomp package \[[@CR13]\]. The R code is provided in Supplement 2.

Results {#Sec6}
=======

Our search yielded 4746 results, of which 28 met the inclusion criteria \[[@CR15]--[@CR42]\] (Fig. [1](#Fig1){ref-type="fig"}, Tables E1-E3). Interrater agreement on the study inclusion was 0.9 \[95% CI 0.8, 1.0\]. Risk of bias was judged as moderate for most studies, mainly due to missing national representativeness of single-centre studies or studies limited to certain geographical regions, or the use of administrative data and ICD-based sepsis case identification, which has known inaccuracies (Table E4). 21/28 studies were included in the meta-analyses; reasons for exclusion from meta-analysis are provided in Fig. [1](#Fig1){ref-type="fig"}. We pooled these 21 studies together with 30 studies included in the previous meta-analysis. Countries covered by the resulting 51 studies are shown in Fig. [2](#Fig2){ref-type="fig"}; 46/51 studies were from high-income countries. The distribution of the studies among WHO regions was as follows: PAR 21.5% (*n* = 11/51), WPR 15.7% (*n* = 8/51), EUR 60.8% (*n* = 31/51), AFR 2.0% (*n* = 1/51), Eastern Mediterranean Region (EMR)/Southeast Asia Region (SEAR)---no studies included. The data sources of the individual studies and their population coverage are provided in Supplement Table E5. We did not identify any community-based studies, and thus stratified studies according to the inpatient setting (ICU/hospital/ED) for further analyses and report the incidence and mortality of treated sepsis cases in the respective setting. Given the small number of studies from LMICs in the strata, no meaningful subgroup analyses by income level were possible.Fig. 1Flowchart of study inclusionFig. 2Country-level coverage of studies on sepsis incidence

Hospital-treated sepsis {#Sec7}
-----------------------

Twenty-eight studies were analysed. The majority were retrospective, based on ICD-coded hospital discharge databases (22/28), chart review (2/28), and case identification in electronic health records (2/28). Two studies used prospective observations to assess sepsis incidence and case fatality. We found a random-effects estimator of 189 \[95% CI 133, 267\] hospital-treated sepsis cases per 100,000 person-years (*τ* = 0.936, Fig. [3](#Fig3){ref-type="fig"}a, last decade estimator: 276 \[95% CI 189, 403\] per 100,000 person-years, *τ* = 0.698, Figure E2A). Differences between WHO regions were not significant (*p *= 0.068, Table E6 and E7). Comparing incidence estimates according to sepsis case definition, we found no significant differences comparing implicit and explicit case identification strategies in ICD-based studies (*p* = 0.169) and between clinical sepsis definitions (*p* = 0.214, Table E8 and E9). The estimated hospital mortality rate was 26.7% \[95% CI 22.9, 30.7\] (*τ* = 0.475, Fig. [4](#Fig4){ref-type="fig"}A) and did not differ significantly between WHO regions (*p *= 0.158, Table E6 and E7) nor between implicit and explicit (*p* = 0.240), or sepsis-1 or sepsis-3 criteria (*p* = 0.769, Table E8 and E9).Fig. 3Random-effects meta-analysis estimators for the incidence of **a** hospital-treated sepsis, and **b** ICU-treated sepsis per 100,000 person-yearsFig. 4Random-effects meta-analysis estimators for the mortality of **a** hospital-treated sepsis, and **b** ICU-treated sepsis

ICU-treated sepsis {#Sec8}
------------------

We meta-analysed the data of 34 studies. One study originated from Rwanda, which differs substantially from other countries in the number of ICUs. Only two ICUs existed in Rwanda at the time of the publication (2013) \[[@CR16]\], representing a complete nationwide survey of ICU-treated sepsis cases. The study found a low estimated incidence rate (2 per 100,000 population) and acts as an outlier with a high leverage in the meta-analysis. We therefore report two random-effects meta-analysis estimators, with and without the data from Rwanda. The random-effects estimator of the ICU-treated sepsis was 58 \[95% CI 42, 81\] per 100,000 person-years (*τ* = 0.998, Fig. [3](#Fig3){ref-type="fig"}B) including all studies and 65 \[95% CI 50, 85\] per 100,000 person-years (*τ* = 0.790) without the Rwanda data. A statistically significant difference was found between the WHO regions (*p* \< .001, Table E6 and E7), with the highest sepsis incidence in PAR . Incidence rates of ICU-treated sepsis did not significantly differ depending on the sepsis case identification (*p* = 0.126, Table E8 and E9). The mortality rate estimate of ICU-treated sepsis patients was 41.9% \[95% CI 36.2, 47.7\] (*τ* = 0.517, Fig. [4](#Fig4){ref-type="fig"}B) (39.9% \[95% CI 35.4; 44.6\], *τ* = 0.405 without Rwanda data), with significant differences between WHO regions (*p = 0.013 *) (Table E6 and E7). Highest mortality rates were found in the AFR. There were no significant differences between sepsis case identification strategies based on ICD-codes or clinical criteria (*p* = 0.211, Table E8 and E9).

ED-treated sepsis {#Sec9}
-----------------

Only four studies reported the incidence of ED-treated sepsis; thus, we presented the data in Table E3 and did not perform a meta-analysis.

Discussion {#Sec10}
==========

This updated and extended systematic review identified 28 new studies, among which 21 provided data to be meta-analysed. It increases our understanding of sepsis epidemiology by synthesizing population-level data from around the world, and to our knowledge, this study represents the largest review of published literature on the population-level burden of sepsis among hospitalized adults. Using a specific search strategy that was designed to increase the number of results from LMICs, we were able to add five studies from two upper middle- and one low-income country to the original systematic review and meta-analyses, which formerly relied exclusively on studies from high-income countries (HICs). Based on a total of 51 studies from 22 countries and 4 WHO regions, we found a pooled incidence of 189 \[95% CI 133, 267\] hospital-treated adult sepsis cases per 100,000 person-years and a mortality rate of 26.7% \[95% CI 22.9, 30.7\]. There was a considerably higher incidence of sepsis observed in more recent studies (from 2008 onwards, +46% compared to the overall time frame). This estimate is mainly based on high-income-country data; it is likely that sepsis epidemiology differs considerably in countries with low and middle income due to a higher burden of infectious diseases \[[@CR43]\], varying patterns of underlying comorbidities such as HIV or *Mycobacterium tuberculosis* infection \[[@CR44]\], limited infection prevention, and fewer resources for sepsis treatment and intensive care \[[@CR45]\]. 85.0% \[95% UI 82.2, 87.4%\] of the incident sepsis cases worldwide occurred in low- and middle-income countries in 2017 according to the IHME sepsis estimates \[[@CR6]\]. This may be one explanation for the considerably lower global sepsis incidence estimate we found compared to the IHME sepsis data (276 \[95% CI 189, 403\] in the past decade vs. 678 \[95% UI 536--876\] cases per 100,000 in 2017 \[[@CR6]\]). However, methodological differences hamper the comparability of the estimates in the IHME study and our meta-analysis. The IHME estimates were based on death certificate data, rather than hospital-based data, and thus capture sepsis cases that contributed to death outside the hospital. Furthermore, IHME estimates included children, which were excluded in most of our underlying studies; notably, the IHME study found very high incidence and mortality among children under 1 year of age.

An interesting finding of the IHME study is that global sepsis cases decreased by 37% between 1990 and 2017. This is contrary to the results from most individual studies included in our review, which found an increase in sepsis incidence over time (see Supplement Tables E1--3). There may be objective reasons for an increase in sepsis rates especially in HICs, likely an ageing population and a high number of elderly with comorbidities and increasing invasive and complex treatments, which may lead to more health care-associated infections and sepsis \[[@CR46]\]. Higher rates of antimicrobial resistance may result in the progression of more infections to sepsis \[[@CR47]\]. Decrease in sepsis incidence found in the IHME study may be driven by a decreasing number of deaths from infectious diseases in LMICs. However, modelling assumptions and imputation steps in the IHME study can introduce considerable bias, as the model inputs were derived from the multiple cause of death (MCOD) data from four countries and hospital data from ten countries. These countries were high- and middle-income countries and data were subsequently extrapolated to low-income countries \[[@CR6], [@CR48]\]. Therefore, longitudinal trends might be unreliable: for example, improvements in burden of sepsis in one country that was used as primary data source would project these benefits to other settings \[[@CR48]\]. This approach leads to lower incidence estimates for high-income countries such as the USA or Sweden compared to data from individual observational epidemiological studies \[[@CR15], [@CR39]\]. This may be due to large variances of the coding of sepsis differences even among high-income countries, and from the undercoding of sepsis in comparison with patient hospital records \[[@CR15], [@CR39], [@CR49]\]. To date, the validity of sepsis coding from MCOD data is unknown.

Likewise, the most likely reason for the observed increase in sepsis incidence in our study may result from the fact that most studies included relied on administrative data, with several inherent methodological limitations. Improved awareness, capacity for diagnosis, and external incentives may have led to a Will Rogers phenomenon (increase in detection of cases and coding) \[[@CR50]\]. Rhee and colleagues found in a recent US study that sepsis incidence rates using clinical criteria in electronic health records were relatively stable (+ 0.6% increase per year), whereas sepsis incidence per claims data increased by + 10.3% per year \[[@CR15]\]. Interestingly, we found no significant differences in meta-analytic estimates comparing different case definitions used to identify sepsis cases in administrative or clinical data. These comparisons, however, are hampered by the low number of studies in each stratum and may also reflect variations in country, settings, and observation years rather than differences arising from case definitions.

To our knowledge, we present the first comprehensive systematic review providing global estimates for the incidence and mortality rates of ICU-treated sepsis among hospitalized adults worldwide. Interestingly, ICU-based studies were mostly prospective and performed in selected ICUs or larger ICU networks, whereas studies on hospital-based sepsis nearly completely relied on administrative data. There was an up to 80-fold difference between the individual estimates of ICU-treated sepsis in the included studies, which may be a reflection of the structural differences in availability and access to intensive care \[[@CR51]\], differences in health care systems, or different underlying study designs. Additionally, ICU capacities have stronger variations than hospital capacities between countries \[[@CR52]\]. Beyond the scarcity of ICUs in many LMICs, access to existing (often private) ICUs may not be affordable for patients or logistically hampered or delayed \[[@CR53]\]. This might contribute to the higher mortality rates in these countries, such as reported from Rwanda with 71.2% among sepsis patients \[[@CR16]\]. In the range of estimates contributed by the other included studies, the Rwanda study appears to be an outlier. However, it might be representative for many LMICs, which implies that it should not be considered as such. It also suggests that there are much larger variances in incidence and mortality rates across countries than reflected in our meta-analyses relying mainly on HIC data. Much of this variance might be explainable by factors on the level of the health care systems that differ across countries or regions.

Despite the strengths of our systematic review, which include data inputs from 51 studies of which several were based on nationally representative datasets, the study has several important limitations. First, we present data on hospital- and ICU-treated sepsis cases rather than population-based estimates. Availability of and access to hospital care is likely to differ between countries. Consequently, a varying proportion of sepsis cases may not receive hospital treatment. In the USA, this proportion was found to be 12% based on an analysis of death certificates \[[@CR54]\]. Second, we observed considerable between-study heterogeneity that may be caused by differences in sepsis definitions, study designs, sampling strategies and study settings. There also remains between-study variance due to variation in the considered time periods and the potential changes in incidence rates and mortality rates over time. Differences in the case mix of the population under observation are also likely to influence sepsis incidence and case fatality estimates. Furthermore, a number of studies used extrapolations to derive nationwide incidence estimates with potential assumptions and modelling. These factors hamper comparability of results within and across WHO regions and between different sepsis case identification methods and limit the generalizability of results. Third, the limitations of retrospective studies reporting on sepsis incidence using administrative data apply to the majority of the included studies. This has driven the overall moderate to high risk of bias assigned to nearly all included studies (94%). Bias may also be introduced by limited national representativeness of studies undertaken in single hospitals. Furthermore, publication bias may have impacted our results. We tried to minimize the risk of publication bias by including databases for grey, unpublished literature in our search. Fourth, not all data sources had complete population coverage, which can lead to an underestimation of the true sepsis incidence if not corrected for. This applies primarily for some nationwide hospital discharge databases and representative hospital samples, which excluded military hospitals, veteran admissions, or psychiatric facilities. Fifth, to avoid dependence of estimates, we selected incidence and case fatality estimates from studies with overlapping or identical data source. This selection was grounded on the available evidence such as the validity of case identification; however, it may also have introduced a certain selection bias. Sixth, the majority of hospital-based studies used administrative data as the data source, thus information on causative pathogens, as well as antimicrobial susceptibility and resistance, are unavailable for most studies. Finally, we were unable to identify studies reporting sepsis-attributable mortality, limiting our understanding of the role of sepsis in the pathway towards death.

In conclusion, in this updated and extended systematic review and meta-analysis, we compiled a comprehensive number of studies with improved geographical representation compared to our previous review. We found high incidence of sepsis across all regions; one out of four sepsis patients did not survive their hospital stay. Substantial gaps remain regarding data availability from low- and middle-income countries, the lack of community-based studies and inherent limitations of epidemiological research based on administrative data, limiting our understanding of temporal trends and geographical disparities. There is an urgent need to improve sepsis surveillance in all countries at the facility and health care provider level, but also to conduct community-based studies that improve our understanding of sepsis occurring outside the hospital setting. An improved documentation and coding of sepsis is needed. In addition, reference standards for sepsis epidemiology research and reporting are crucial for a better understanding of the problem and comparability of estimates, and ultimately to improve our understanding of the medical and economic burden of sepsis.
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